More recently, a PKPD model incorporating In vitro cellular growth dynamics in a 2D-cultured HER1-mutant glioblastoma cell line (SF268), pharmacokinetics, and in vivo glioblastoma growth was developed to optimize lapatinib dosing schedules for the treatment of glioblastoma patients9. Here, EGFR is linked to glioblastoma.